A series of recent brain-imaging studies has begun to explain a central mystery of the psychedelic experience: why people on psilocybin report that memories seem to blend with what they are actually seeing. Researchers have now traced this effect to specific circuit-level changes, from the thalamus down to the primary visual cortex, that dampen incoming sensory signals while amplifying internally stored images. The findings carry direct implications for mental health treatment, where the ability to revisit and reprocess old memories could be harnessed, but also for understanding when that same mechanism goes wrong.
The Thalamic Gate Swings Open
The thalamus acts as the brain’s central relay station, filtering which sensory signals reach conscious awareness and which get discarded. Under psilocybin, that filter loosens. Human fMRI data published in NeuroImage showed that psilocybin induces spatially constrained alterations in thalamic functional organization and connectivity. Rather than a uniform flood of activity, the drug reorganizes specific thalamic subregions, changing how they talk to cortical areas involved in vision, memory, and self-referential thought.
This selective disruption matters because it explains why the psychedelic state does not simply produce noise. The thalamus does not shut down entirely or open all channels at once. Instead, particular relay pathways shift their connectivity patterns, which means some sensory streams weaken while feedback loops from higher-order cortical regions, the ones that store autobiographical memories and abstract associations, gain unusual influence over perception. The result is a brain state in which what a person remembers and what they see begin to occupy the same neural real estate, effectively fusing memory with perception.
Slow Waves Push Perception Toward Memory
Animal research has pinpointed a specific electrical signature tied to this shift. When awake mice received serotonergic psychedelic-like compounds, including the 5-HT2A receptor agonists DOI and TCB-2, cortex-wide population voltage imaging captured increased low-frequency oscillatory activity at approximately 5 Hz in both primary visual cortex (V1) and retrosplenial cortex (RSC). The retrosplenial cortex is tightly linked to spatial memory and scene reconstruction, so boosting synchronized slow waves across both regions creates a direct electrical bridge between incoming visual data and stored spatial memories.
Separate mechanistic work in mice confirmed that 5-HT2A receptor activation in V1 produces divisive suppression of sensory input across polysynaptic circuits. In practical terms, the drug turns down the volume on fresh visual information at the network level. When external signals weaken and slow oscillations synchronize visual and memory-related cortex, the brain’s internal imagery gains a competitive advantage over the outside world. This is not a metaphor, it is a measurable change in how neural populations encode information.
Research reported by ScienceDaily coverage earlier this year described how psychedelics can quiet the brain’s default reality-monitoring systems, with slow brain waves shifting perception toward memory. That team tracked how the shift unfolds in real time, adding a temporal dimension to the circuit-level picture built by the animal studies. Together, these findings suggest that psychedelic compounds do not simply overlay hallucinations onto normal perception; they actively retune the timing and strength of cortical rhythms so that internally generated memories and imagery can dominate perception.
Human Visual Systems Rewire Under Psilocybin
Direct human neuroimaging has confirmed that psilocybin does not just reduce visual cortex activity; it redirects the flow of information within the visual hierarchy. A study published in Molecular Psychiatry examined psilocybin-related changes in visual system inputs and effective connectivity, finding reduced sensitivity of visual regions and altered hierarchical signaling consistent with internally generated imagery replacing external stimuli as the dominant input. In other words, the brain begins processing its own memory-derived images through the same pathways it normally reserves for real-world sight.
Behavioral evidence reinforces this interpretation. An eye-tracking and EEG study published in Neuroscience of Consciousness found that under high-dose psilocybin, participants showed increased fixations on salient regions, shorter inter-fixation distances, and higher entropy in their scanpaths. The eyes still moved, but they locked onto emotionally or perceptually meaningful features while the overall scanning pattern grew more chaotic. This suggests that psilocybin biases the visual system toward pattern significance, the kind of processing that memory and emotional salience typically drive, rather than the systematic environmental scanning that characterizes sober perception.
Shared Circuitry With Hallucination Disorders
One of the more striking findings from recent synthesis work is that the neural pattern behind psychedelic visual experiences closely resembles what happens in Lewy body diseases, a group of neurodegenerative conditions that produce vivid visual hallucinations. A peer-reviewed comparison published in Schizophrenia Bulletin identified convergent neuroimaging patterns: associative cortex hyperactivity paired with sensory cortex hypoactivity, along with receptor-level links through 5-HT2A involvement. In both conditions, higher-order brain regions that handle meaning, context, and memory become overactive while the regions that process raw sensory data quiet down, allowing internally generated images to intrude into perception.
This overlap creates a productive tension for researchers and clinicians. On one hand, the shared circuitry validates the idea that psychedelic therapy works partly by allowing patients to re-experience and reprocess traumatic or deeply encoded memories in a perceptually vivid way. On the other hand, it raises a caution: the same mechanism that enables therapeutic breakthroughs in depression or PTSD is also implicated when hallucinations become chronic, intrusive, and untethered from reality testing. The challenge is to harness this circuit-level plasticity in controlled settings, with careful dosing and psychological support, without nudging vulnerable brains toward pathological patterns seen in degenerative disease.
Therapeutic Promise and Scientific Next Steps
The emerging picture is that psilocybin and related compounds temporarily rebalance the competition between outside-in and inside-out information flow. By loosening the thalamic gate, enhancing slow-wave synchrony between sensory and memory regions, and dampening early visual responses, the drugs allow autobiographical material and latent associations to surface as if they were part of the current scene. For patients working through entrenched depressive narratives or trauma, this can make abstract insights feel immediate and emotionally compelling, a quality many describe as the core of their therapeutic breakthroughs.
Yet the same properties that make psychedelic states powerful also make them risky. Individual variability in receptor expression, structural connectivity, and pre-existing vulnerability to psychosis or neurodegeneration may determine whether a person experiences a transient, insightful blending of memory and perception or a destabilizing loss of reality boundaries. Future work will likely draw on large-scale repositories such as NCBI databases to integrate genetic, imaging, and clinical data, refining who is most likely to benefit and who may require alternative approaches. As the field moves forward, translating these detailed circuit maps into practical screening tools and dosing protocols will be crucial if psychedelic-assisted therapies are to expand without repeating past waves of overenthusiasm and backlash.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
